TriLink signs TINA modified oligonucleotide licensing contract with QuantiBact

TINA molecules placed at the 5′ end of primers, stabilize duplex formation.

The intercalators have high sensitivity and specificity of endpoint and PCR.

QuantiBact managing director and CEO Palle Schelde said, "At QuantiBact we strive to make our technologies available throughout the research and diagnostic communities."

TINA are applied where an enhanced Tm is required such as triplex formation or potentially even gene silencing.

TriLink president and CEO Richard Hogrefe said, "At TriLink we pride ourselves on our quality and our ability to handle unique nucleic acid modifications. This makes us an ideal manufacturer of TINA oligos."